scholarly journals 4CPS-104 Chemotherapy treatment in colorectal cancer patients older than 70 years at a tertiary hospital

Author(s):  
JJ Alcaraz Sanchez ◽  
JC del Río Valencia ◽  
R Tamayo Bermejo ◽  
I Muñoz Castillo
2019 ◽  
Vol 37 (15_suppl) ◽  
pp. 6536-6536 ◽  
Author(s):  
Phichai Chansriwong ◽  
Suwannee Sirilerttrakul ◽  
Nopakan Wannakansophon ◽  
Patamaporn Tangteerakoon ◽  
Suluck Vongterapak ◽  
...  

6536 Background: Colorectal cancer is an important health problems in Thailand; chemotherapy remains the most suitable treatment for metastatic patients. Chemotherapy treatment that was once delivered only in hospital environments is now administered at patient's home that helping patients to live normal lives during receiving chemotherapy. The chemotherapy regimens are based on a 48 hours 5-fluorouracil infusion combined that need patients to be hospitalized, consequence to decrease QOL and increase cost of treatment. Aims: Compares the QOL score, patients’ satisfaction and cost difference in treating ambulatory chemotherapy (AC) patients compared with inpatient treatment. Methods: An observational cohort which enrolled 156 patients at the Ramathibodi hospital from Dec 2015 to Nov 2016. AC administered by the central venous access device (CVAD). The regimen as FOLFOX or FOLFIRI, 5-FU were in the elastomeric infusion pump and administered at the patients’ home. Nurse coordinators followed up with the patients by phone. The FACT-G and FACT-C scale, patients’ satisfaction and cost of treatment questionnaire were collected at time of enrolment, 2 months and end of treatment. Results: 156 patients are enrolled that 111 patients treated with AC and 45 patients treated with inpatient. 134 returned the questionnaire (response rate 86%). Intention to treat analysis revealed significantly improved in social wellbeing and FACT-G (p <0.001) in AC group. Significant higher administration, service and overall satisfaction score in AC group. The AC reduced cost about 483 US dollars per cycle of chemotherapy. Conclusions: Ambulatory chemotherapy helps colorectal cancer patients to live normal lives by administer treatment at patients' home and results to significantly improve in quality of life especially in social wellbeing and more satisfaction. Moreover, ambulatory chemotherapy reduced cost of chemotherapy treatment.


2013 ◽  
Vol 16 (3) ◽  
pp. A195
Author(s):  
P. Solano-Murillo ◽  
L.R. Sánchez-González ◽  
L.M.A. Balderas-Peña ◽  
GA Hernández-Chávez

2016 ◽  
pp. 3-6
Author(s):  
Marie-Rose Dwek ◽  
Lorna Rixon ◽  
Alice Simon ◽  
Catherine Hurt ◽  
Stanton Newman

Introduction: Research suggests that chemotherapy may be related to decline in patients cognitive functions. Objectives: To assess the feasibility and acceptability of a multi-site study designed to examine the nature and extent of chemotherapy-related cognitive changes in colorectal cancer patients. Method: Data was collected over 8 months using objective and self-reported measures of cognitive functioning and self-reported quality of life, fatigue and mood questionnaires. The assessment battery was administered pre- and mid-chemotherapy treatment to a consecutive sample of colorectal cancer patients across three Londonbased NHS Trusts. Participants included patients who had undergone colorectal surgery and were scheduled to have adjuvant chemotherapy treatment, or no further cancer treatment. Main outcome measures: Recruitment procedures, rate of recruitment, suitability of exclusion/inclusion criteria, acceptability of data collection procedures and the battery, and attrition rates. Results: From 1 April 2014 to 1 December 2014, 42 eligible participants were invited to take part in the trial. Of the 17 that completed pre-chemotherapy assessments, only 1 withdrew at follow-up due to reasons of ill health from disease recurrence. All participants completed the entire battery and indicated that they found the trial acceptable. Conclusions: What went wrong: Strained researcher resources; loss of eligible participants to competing studies, restrictive upper age limit. Possible solutions: Removal of upper age limit, an increased dedicated research team to increase rate of recruitment. The large multi-site study is feasible with suggested amendments and is acceptable to patients and medical teams. Acceptability of trial to medical teams is further evidenced by requests of collaboration from two additional London based NHS Trusts. Lessons learned: This feasibility trial provides evidence to other researchers designing similar studies in this area of an acceptable design and the need for appropriate funding for resources to recruit large enough consecutive samples of patients with solid tumour cancers.


BMC Cancer ◽  
2017 ◽  
Vol 17 (1) ◽  
Author(s):  
Bello Arkilla Magaji ◽  
Foong Ming Moy ◽  
April Camilla Roslani ◽  
Chee Wei Law

2021 ◽  
Vol 9 (32) ◽  
pp. 9804-9814
Author(s):  
Dadang Makmun ◽  
Marcellus Simadibrata ◽  
Murdani Abdullah ◽  
Ari F Syam ◽  
Hamzah Shatri ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document